Formycon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Formycon şirketinin toplam hissedar öz sermayesi €576.3M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €947.8M ve €371.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€40.62m
Eşitlik	€576.30m
Toplam yükümlülükler	€371.48m
Toplam varlıklar	€947.78m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: FYB 'nin kısa vadeli varlıkları ( €95.9M ) kısa vadeli yükümlülüklerini ( €45.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: FYB 'un kısa vadeli varlıkları ( €95.9M ) uzun vadeli yükümlülüklerini ( €325.9M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: FYB borçsuzdur.

Borcun Azaltılması: FYB un 5 yıl önce borcu yoktu.

Borç Kapsamı: FYB un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: FYB şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Formycon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Investor sentiment improves as stock rises 17%

First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Investor sentiment improves as stock rises 15%

Price target decreased by 8.7% to €87.00

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Price target decreased by 12% to €96.25

New minor risk - Shareholder dilution

Price target decreased by 8.9% to €105

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

New minor risk - Share price stability

Price target decreased by 7.5% to €107

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 8.8% to €115

New minor risk - Share price stability

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Price target increased to €126

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Price target increased to €107

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Full year 2021 earnings: EPS and revenues miss analyst expectations

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Price target increased to €87.00

Price target increased to €75.00

Price target decreased to €70.00

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Full year 2020 earnings released

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

New 90-day high: €75.40

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Price target raised to €46.45

New 90-day high: €51.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

New 90-day high: €37.50

New 90-day high: €30.70

First half earnings released

Price target raised to €36.28

New 90-day high - €27.20

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin